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Background/aim: Histopathological examination is crucial for the effective management of endometrial polyps. Immunohistochemical
markers such as p16 and c-Kit may facilitate the differential diagnoses of benign and malignant polyps. The aim of the present study was
to explore the expression levels of c-Kit (CD117) and p16 in endometrial polyps of postmenopausal women.
Materials and methods: Twenty-five hysterectomy specimens with malignant endometrial polyps and hysterectomy or polypectomy
specimens featuring 55 benign polyps were studied. The polyps were immunohistochemically stained for p16 and c-Kit, and differences
in the expression levels of these proteins in the glandular and stromal components of benign polyps and the benign regions of the
malignant polyps were assessed by using Fisher’s exact test.
Results: The glandular components of malignant polyps exhibited significantly more intense p16 immunostaining than did benign
polyps. Most immunoreactive cells were glandular cells exhibiting tubal metaplasia. The stromal components of either type of polyp did
not differ in terms of p16 immunostaining. The extent of c-Kit immunostaining in benign and malignant polyps was similar.
Conclusion: The extensive tubal metaplasia in and the p16 immunoreactivity of the glandular components of malignant polyps may be
useful to distinguish such polyps from benign polyps.
Key words: p16, c-Kit, endometrial polyp, tubal metaplasia

1. Introduction
An endometrial polyp is a common benign lesion
extending from the endometrial surface. A polyp is
composed of endometrial glands and (at least) a focally
fibrous stroma with thick-walled vessels (1). The incidence
of malignant polyps is low, but the risk increases after
menopause. The incidence of malignancy confined to
the polyps is 0.8%–8%, but 10%–34% of endometrial
carcinomas in postmenopausal women are associated with
endometrial polyps (1–3).
Although no consensus on polyp management has
emerged, such management should be conservative when
Doppler flowmetry data are normal and no atypical change
is evident upon endometrial biopsy (4). It is not always
possible to sample the polyp or to identify a malignancy
via endometrial biopsy; this means that false-negative test
results are not uncommon (5,6). Much effort has been
devoted to the detection of polyps associated with a high
risk of malignancy; timely diagnosis and treatment of
* Correspondence: lutfiyeuygur@gmail.com
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such polyps are essential. Risk factors include older age,
menopausal status, abnormal uterine bleeding, diabetes,
hypertension, and a polyp diameter of >1.5 cm (2,3,7–9).
Few studies have sought to define immunohistochemical
biomarkers that may distinguish polyps accompanying
malignancies from benign polyps. Such studies have
compared the immunohistochemical staining intensities
of Ki-67, Bcl-2, COX2, the estrogen receptor, and the
progesterone receptor in benign and malignant polyps
(10,11).
p16 is a cyclin-dependent inhibitor of kinase-4,
and p16 expression has been used in the differential
diagnoses of polyps, hyperplasia, adenocarcinomas of
the endometrium, malignant lesions arising from the
transformation of benign lesions, and many other types of
both malignant and benign lesions (12–16).
c-Kit is a protooncogene encoding the transmembrane
tyrosine kinase receptor termed CD117. The expression
levels of c-Kit in malignant and benign endometrial
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polyps, adenocarcinomas, and many other types of
benign and malignant lesions have been examined
immunohistochemically (17–20).
The aim of the present study was to evaluate p16
and c-Kit expression levels in the stromal and glandular
epithelia of malignant and benign polyps.
2. Materials and methods
Twenty-five postmenopausal endometrial polyps that
had become malignant and 55 postmenopausal benign
endometrial polyps were examined. All polyps were
collected from patients diagnosed by the pathology
departments of the Zeynep Kamil Maternity and
Pediatric Research and Training Hospital and the Fatih
Sultan Mehmet Research and Training Hospital between
2004 and 2014. The ethics committees of both hospitals
approved the present work. Complete hysterectomy and
bilateral salpingo-oophorectomy specimens were available
for all malignant cases. The hysterectomy specimens of 31
benign cases and polypectomy specimens (only) of the
other 24 cases were also available.
Data on macroscopic specimen assessments and
pathological and clinical findings were collected by
chart review. All sample slides were reexamined by two
pathologists under light microscopes.
An endometrial polyp was defined as a focal
proliferation of the endometrium in polypoid form,
combined with a sclerosing stroma and thickened wall
vessels. A malignant polyp or a malignant region in an
otherwise benign polyp was defined as an intraepithelial
or invasive carcinoma replacing at least a portion of a
polyp (21). Menopause was defined as amenorrhea >12
months in duration.
Diagnostic tissue blocks were excised from the benign
and malignant (if present) portions of all polyps, and
immunohistochemical staining for p16 and c-Kit (CD117)
followed. We stained formalin-fixed paraffin-embedded
tissue sections using a manual polymer detection system
after epitope retrieval by heating in citrate buffer. The
following prediluted (thus, ready-to-use) primary
antibodies were employed: anti-p16 (INK 4; BioGenex)
and CD117/c-Kit (Thermo Fisher Scientific).
p16 positivity was evidenced by brown staining of the
nucleus and/or the cytoplasm. The extent of nuclear and
cytoplasmic staining in each section was assessed in terms
of cell percentage and categorized as follows: 1) negative:
no staining; 2) + (focally positive): less than 5% of cells
stained; 3) ++ (regionally positive): 5%–50% of cells
stained; and 4) +++ (diffusely positive): more than 50% of
cells stained (22).
For c-Kit, cells exhibiting either cytoplasmic
or membranous staining were considered positive.
Immunostaining data included the extent of staining

(focal: <10% of cells; intermediate: 10%–50%; diffuse:
>50%) and staining intensity (1+ to 3+) (17).
SPSS 13.0 (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. The p16 and c-Kit immunostaining data
from benign polyps and the benign portions of malignant
polyps were compared using Fisher’s exact test. P < 0.05
was considered to indicate statistical significance.
3. Results
Of the 80 endometrial polyps, 25 (31.25%) were malignant
and 55 (68.75%) were benign. The mean patient ages
were 60.8 years for those with malignant polyps and 58
years for those with benign polyps. Histopathologically,
the tumors were as follows: 10 serous adenocarcinomas
(40%), 9 endometrioid adenocarcinomas (36%), 4
clear cell carcinomas (16%), and 2 (8%) endometrial
intraepithelial carcinomas (EICs). All malignancies were
in postmenopausal women. The smallest and largest
diameters of malignant polyps were 0.5 cm and 7 cm,
respectively. The mean polyp diameter was 3.4 cm. For
benign polyps, the smallest and largest diameters were 0.2
cm and 2.7 cm, respectively. The mean diameter of benign
polyps was 1.4 cm (Table 1).
All malignancies had initially invaded the polyp tips,
and all were restricted to the polyps with the exception
of two cases of serous adenocarcinoma in which both the
pedicles of the polyps and the deep myometrium had been
invaded.
The endometrium proper was malignant (accompanied
by polyp carcinoma) in only one case each of serous and
clear cell carcinoma. In the former case, the tumor had
metastasized to the uterine serosa and right pelvic lymph
nodes. In the other case, the carcinoma was restricted to
the uterus.
Endometrial samples of all malignant polyps were
available. Endometrial curettage of 2 of the 25 malignant
polyps yielded negative results (8%). However, malignancy
was evident in the hysterectomy materials (8%).
p16 and c-Kit expression levels were evaluated in
the stroma and glandular epithelia of the polyps. Upon
glandular staining for p16, 21 of the 25 malignant polyps
(84%) were immunopositive. Staining was generally focal
or regional, thus rarely diffuse. Of the benign polyps, only 7
(13%) were positive for p16; this difference was significant
(P < 0.001). Morphologically, the immunopositive glands
were benign in appearance, but most were overlaid by cells
exhibiting secretory tubal metaplasia. Some of these glands
were cystic, dilated, and overlaid by simple epithelium. All
staining was both cytoplasmic and membranous (Figures
1a–1d). Upon stromal staining for p16, 9 (36%) of the 25
malignant polyps were positive, as were 15 (27%) of the 55
benign polyps; however, this difference was not significant
(P = 0.44) (Table 2)
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Table 1. Histopathological features of malignant polyps (n = 25 cases).
Case

Age

Malignancy originating
from endometrial polyp

Size of the polyp (cm)

Size of tumor (cm)

1

46

Adeno Ca

2.5

1.6

2

78

Adeno Ca

3

2

3

38

Adeno Ca

2

1 and 0.5

4

56

Serous Ca

3.5

3

5

75

EIC

5

0.5

6

69

Serous Ca, EIC

3

0.6 and 0.3

7

71

Clear cell Ca

5

4

8

58

Adeno Ca

7

6

9

70

Serous Ca

1.5

0.5

10

65

Clear cell Ca

6

5

11

46

Serous Ca

3

2.5

12

67

Clear cell Ca

3 and 0.5

0.3 and 0.2

13

74

Serous Ca

3

2.5

14

42

Adeno Ca

4

0.5

15

66

Serous Ca

3

2.5

16

64

Adeno Ca

3

2

17

49

Serous Ca

1.5

1

18

62

Adeno Ca

3

3

19

62

Serous Ca, EIC

2

1

20

61

Serous Ca, EIC

3.5

1

21

58

Adeno Ca

3

1

22

63

EIC

4

1.4

23

50

Serrous Ca, EIC

2.5

0.8

24

71

Adeno Ca

4.5

1.5

25

59

Clear cell Ca

3.2

1.2

EIC: Endometrial intraepithelial carcinoma, Ca: carcinoma.

Upon glandular staining for c-Kit, 17 of the 25
malignant polyps (68%) were immunopositive to varying
intensities (focal, intermediate, or diffuse); 33 of the 55
benign polyps (60%) were similarly immunopositive.
Upon stromal staining, 17 malignant polyps (68%) were
immunopositive to varying intensities, as were 44 of the
benign polyps (80%). Neither the glandular nor stromal
staining levels for c-Kit differed significantly between the
two groups (P = 0.62 for glandular staining and P = 0.26
for stromal staining) (Table 3).

1824

4. Discussion
The mean ages of patients with malignant and benign
polyps were 60 and 58 years, respectively, compatible
with literature data. Previously reported mean ages were
63.6 and 64.4 years for those with malignant polyps, and
56.5 and 61.7 years for those for benign polyps (11,23).
However, Hui et al. reported that the mean age of patients
with malignant polyps was 67 years. This may be because
the cited authors included only patients with serous
adenocarcinomas, which occur in patients older than
those with endometrioid adenocarcinomas (24).
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Figure 1. Malignancy originating from endometrial polyp. a, b) Hematoxylin and eosin staining: glands exhibiting tubal metaplasia
(arrows) (original magnification: a, 100×, b, 200×). c, d) p16 immunostaining: epithelial staining intensities in individual glands are
variable but more consistent in cells exhibiting tubal metaplasia (arrows) (original magnification: c, 100×, d, 200×).
Table 2. Immunohistochemical expression levels of p16 in benign and malignant polyps (intensity/distribution
of staining).

Stromal

Glandular

p16
Staining intensity

Malignant (n = 28)

Benign (n = 55)

+

12 (48%)

5 (9%)

++

7 (28%)

2 (4%)

+++

2 (8%)

0

-

4 (16%)

48 (87%)

+

3 (12%)

9 (16%)

++

4 (16%)

4 (7%)

+++

2 (2%)

2 (4%)

-

16 (64%)

40 (73%)

P

<0.001

0.44

1825

KOÇ et al. / Turk J Med Sci
Table 3. Immunohistochemical expression levels of c-Kit in benign and malignant polyps (intensity/distribution
of staining).

Stromal

Glandular

c-Kit
Staining intensity

Malignant (n = 25)

Benign (n = 55)

+/+

3 (12%)

16 (30%)

++ / +

3 (12%)

10 (18%)

++ / ++

6 (24%)

5 (9%)

++ / +++

5 (20%)

2

-/-

8 (32%)

22 (40%)

+/+

5 (20%)

16 (30%)

++ / +

3 (12%)

14 (26%)

++ / ++

4 (16%)

10 (18%)

++ / +++

5 (20%)

4 (6%)

-/-

8 (32%)

11 (20%)

All malignant polyps were found in postmenopausal
patients. Except for one, all were >1.5 cm in diameter; the
median diameter was 3.4 cm. The median diameter of the
benign polyps was 1.4 cm. These findings are in line with
earlier data indicating that a polyp diameter of >1.5 cm
and postmenopausal status are principal risk factors for
malignancy (2,3,8,9).
We found that all malignancies were restricted to the
polyps; the endometrium proper was not involved and
extrauterine involvement was evident in only one case that
also exhibited involvement of the endometrium proper.
This was consistent with the view of Hui et al.: involvement
of the endometrium proper is indicative of extrauterine
involvement. Also, all malignancies involved the polyp
surfaces, in agreement with the data of Hui et al. (21).
The common types of malignancies originating from
the surfaces of polyps are endometrioid adenocarcinoma
(81.5%) and serous adenocarcinoma (20%). Clear cell
carcinoma is comparatively rare (1,25). In our present
study, the rates were 36%, 40%, and 16% for endometrioid,
serous, and clear cell carcinomas, respectively; 8% of
the cases were EICs. Our relatively high frequency of
serous adenocarcinoma may be attributable to the fact
that we used not only morphological criteria, but also
immunohistochemical methods and p53 marker detection
to diagnose such adenocarcinomas. Overexpression of
mutant p53 protein is a surrogate marker of uterine serous
adenocarcinoma (21).
Although transvaginal ultrasound is important for
the detection of endometrial polyps associated with
malignancy, histopathological examination is essential
when it is sought to rule out malignancy (1,4,21,26).

1826

P

0.62
(3%)

0.26

Endometrial polyps, and malignancies on such polyps, can
be missed even on endometrial biopsy (5,6,21,25). Guido
et al. found that, of 11 false-negative endometrial biopsies
performed using a Pipelle curette, the malignancies were
restricted to the polyps in 5 cases (6). Onderza et al.
incidentally diagnosed a malignancy in the hysterectomy
specimen in only 1 of 27 patients with endometrial polyps
(25). We detected malignancies accompanying polyps
in hysterectomy specimens of two cases in which the
endometrial samples had yielded benign diagnoses (8%).
Antunes et al. immunohistochemically evaluated
the expression of Ki-67, Bcl-2, and COX2 in the stromal
and glandular epithelia of malignant and benign polyps
to explore the relationship between postmenopausal
development of endometrial polyps and carcinogenesis.
The COX2 expression level was higher in malignant
polyps, but those of Ki-67 and Bcl-2 did not differ
between malignant and benign polyps (10). Another
study immunohistochemically compared the levels of
estrogen and progesterone receptors expressed by benign
and malignant polyps; the stromal expression level of the
estrogen receptor was lower in malignant polyps (11).
The protein p16 is a cell cycle-dependent kinase
inhibitor that negatively regulates the cell cycle. p16 is
considered a potent tumor suppressor gene because it causes
cell cycle arrest. Frequent structural alterations in p16
have been identified in various malignancies. Inactivation
of p16 by gene deletion, mutation, or hypermethylation
is evident in some endometrial carcinomas. Tsuda et
al. showed that promoter hypermethylation triggered
p16 protein loss in 50% of endometrioid endometrial
carcinomas and 44% of endometrial hyperplasias. Thus,

KOÇ et al. / Turk J Med Sci
alterations in p16 expression are important in endometrial
tumorigenesis (27). p16 immunostaining has been used
to identify normal endometrial tissue and endometrial
polyps, and to distinguish endometrial polyps from
hyperplastic tissue and endometrial carcinomas (12–14).
Stewart et al. revealed that normal cyclical endometrium
showed patchy glandular and focal stromal p16 expression
while endometrial polyps displayed more extended
glandular and stromal immunoreactivity for p16. Thus,
p16 expression can help to distinguish polypoid and
nonpolypoid mucosa (12). Moritani et al. showed that
stromal p16 expression differed significantly between
endometrial polyps (89%) and endometrial hyperplasia
(3%). Thus, it can be a useful marker for diagnosis,
especially in fragmented specimens (13). Buchynska et al.
detected higher expression levels of p16 in endometrial
adenocarcinomas compared with endometrial polyps
(14). However, differences in immunostaining intensities
between benign and malignant polyps have not previously
been studied.
We detected focal and regional immunostaining for p16
in the glandular regions of 7 of the 55 benign polyps (13%)
and 21 of the 25 malignant polyps (84%). Immunoreactivity
was evident in glands formed by cells exhibiting tubal
secretory metaplasia. Steward et al. found that the glandular
regions of 10%–80% of benign endometrial polyps stained
positive for p16; the immunopositive cells usually exhibited
ciliated metaplasia (12).
Carlson et al. detected metaplastic changes in 39 of 83
endometrial polyps in which endometrial intraepithelial
neoplasms were evident; 14% of the changes were tubal
secretory metaplasias (28). Endometrial metaplasia
is a complex grouping of various forms of epithelial
proliferation. Any possible relationship between
metaplasia and endometrial adenocarcinoma remains
unclear. (29). As is true of polyps, tubal metaplasias are
common in peri- and postmenopausal women, and are
associated with estrogenic stimulation (30). Estrogen
receptor levels are elevated in the glandular epithelia of
endometria that contain polyps as in tubal metaplasia (11).

Horree et al. showed that such tubal metaplasia regions
were consistently immunopositive for p16, and also for cell
cycle proteins, HIF-1α, CAIX, and Glut-1, suggesting that
endometrial tubal metaplasia is potentially a premalignant
endometrial lesion (30).
Although both the etiopathogenesis of endometrial
polyps and the malignancies that can develop on such
polyps remain poorly understood, our findings suggest
that polyps may develop upon estrogenic stimulation
and that diffuse tubular metaplasia may be a stage in the
development of malignancy.
The protooncogene c-Kit encodes a 145-kDa
transmembrane tyrosine kinase receptor (termed CD117),
the ligand of which is stem cell factor (SCF). c-Kit is
weakly to moderately expressed in many normal, benign,
and malignant tissues. Mutational mechanisms aside,
it has been suggested that c-Kit, together with SCF, may
promote tumorigenesis by stimulating tissue growth in an
autocrine and/or paracrine manner (17). c-Kit is expressed
in some solid tumors and may contribute to tumorigenesis
and malignant transformation (18,27). Arber et al. and
Scobie et al. investigated c-Kit expression in endometrial
carcinomas; immunopositivity of varying intensity
(50%–100%) was evident (18,31). Elmore et al. detected
cytoplasmic staining of epithelial cells of the endometria in
4 of 9 adenocarcinomas and 1 endometrial polyp (17). No
work has been done yet to compare benign and malignant
polyps in terms of c-Kit expression level. We found that
the glandular and stromal components of both benign
and malignant polyps were immunostained to varying
intensities. We found no difference between benign and
malignant polyps in terms of c-Kit immunostaining.
Thus, both tubal metaplasia and p16 immunoreactivity
may aid in the diagnosis of malignancies accompanying
polyps and may appropriately alert pathologists, especially
if no malignant cells are detected in small and/or
fragmented biopsy samples. Clearly, clinical, pathological,
immunohistochemical, and molecular studies on the
etiology and carcinogenesis of endometrial polyps with
larger patient numbers are needed to support our assertion.
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